CI Command
Center

A competitive intelligence command center for cholangiocarcinoma, integrating live ClinicalTrials.gov pipeline data with PubMed publication analytics. Tracks sponsor activity across clinical phases, maps molecular target landscapes, identifies key opinion leaders through publication network analysis, and synthesizes strategic insights — all computed in-browser from public APIs.

ClinicalTrials.gov APIPubMed E-utilitiesPipeline AnalyticsKOL MappingSponsor TrackingCo-Authorship NetworksD3 VisualizationsReal-Time Data

Disclaimer: This is a portfolio demonstration using publicly available data from ClinicalTrials.gov and PubMed. It loads pre-cached demo data by default for instant presentation, with an optional toggle for live API queries. This tool is NOT intended for commercial competitive intelligence decision-making and should NOT inform actual brand strategy or Medical Affairs activities.

Loading clinical trials data...

Technical Architecture

Data Pipeline

ClinicalTrials.gov v2 API provides structured trial data (phase, status, enrollment, interventions). PubMed E-utilities (esearch + esummary) supply publication metadata. Both sources are transformed client-side with molecular target extraction via keyword matching against intervention names.

State Architecture

React Context + useReducer manages cross-tab state: trial/publication data, tracked sponsors, active filters, and view selections. 13 action types handle data loading, filtering, and cross-tab interactions. Demo mode loads pre-cached JSON; live mode queries APIs directly.

Visualization Layer

D3 sub-packages (d3-scale, d3-force, d3-zoom) compute layouts and scales; React renders SVG elements via JSX. The co-authorship network uses force-directed simulation with collision detection. Recharts handles standard charts (treemap, bar). All charts use the clinical teal palette.

References

ClinicalTrials.gov API v2. U.S. National Library of Medicine. https://clinicaltrials.gov/data-api/api
NCBI Entrez E-utilities. National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/books/NBK25501/
Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168-2179.
Abou-Alfa GK, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy). Lancet Oncol. 2020;21(6):796-807.
Valle J, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273-1281.
Oh D-Y, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1). NEJM Evid. 2022;1(8).

CI CommandCenter